title: [The prevention of deep venous thrombosis in patients undergoing an internal arteriovenous fistula intervention].
abstract: Twenty patients, submitted to internal arteriovenous fistula procedure, were randomly assigned to one of the following treatments: defibrotide 400 mg b.i.d. IM (starting the day before surgery and continuing for the following 7 days); calcium heparin 5,000 IU t.i.d. SC (since the day of surgery and for the following 7 days). No deep venous thrombosis or thrombosis of the fistula were noticed during both treatments and no side effects were observed. In the defibrotide group, ELT showed a significant decrease (-40%) attesting an improvement of fibrinolysis without a plasminogen abatement. These findings indicate that defibrotide represent an effective alternative to calcium heparin for antithrombotic prophylaxis of A-V fistula in uremic patients.
authors.affiliation: Istituto di Patologia Chirurgica, Università degli Studi di Palermo.
authors.forename: F P
authors.initials: FP
authors.lastname: Picone
authors.forename: A
authors.initials: A
authors.lastname: Lombardo
authors.forename: L M
authors.initials: LM
authors.lastname: Rapisarda
authors.forename: M
authors.initials: M
authors.lastname: Giambruno
authors.forename: C
authors.initials: C
authors.lastname: Gerosa
authors.forename: M
authors.initials: M
authors.lastname: Nazzari
mesh_terms: D001166:Arteriovenous Shunt, Surgical; D004361:Drug Tolerance; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000517:prevention & control*; D014511:Uremia / Q000097:blood / Q000601:surgery
chemical_list: D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C006871:calcium heparin; C036901:defibrotide; D006493:Heparin